Bandaríkin - enska - NLM (National Library of Medicine)

avkare, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets, usp are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below: acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis , or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis , or streptococcus pneumoniae. community-acquired pneumonia due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, streptococcus pneumoniae, chlamydophila pneumoniae (twar), or mycoplasma pneumoniae. the efficacy and safety of clarithromycin extended-release tablets, usp in treating other infections for which other formulations of clarithromycin are approved have not been established. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets, usp and

Bandaríkin - enska - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin extended-release tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin extended-release tablets are indicated only for acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and community-acquired pneumonia in adults. the efficacy and safety of clarithromycin extended-release tablets in treating other infections for which

Kanada - franska - Health Canada

sun pharma canada inc - clarithromycine - comprimé (à libération prolongée) - 500mg - clarithromycine 500mg - other macrolides

Kanada - franska - Health Canada

sun pharma canada inc - clarithromycine - comprimé - 250mg - clarithromycine 250mg - other macrolides

Kanada - franska - Health Canada

sun pharma canada inc - clarithromycine - comprimé - 500mg - clarithromycine 500mg - other macrolides

Kanada - franska - Health Canada

sun pharma canada inc - clarithromycine - poudre pour suspension - 250mg - clarithromycine 250mg - other macrolides

Kanada - franska - Health Canada

sun pharma canada inc - clarithromycine - poudre pour suspension - 125mg - clarithromycine 125mg - other macrolides

Bandaríkin - enska - NLM (National Library of Medicine)

rebel distributors corp. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis , or streptococcus pneumoniae acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae community-acquired pneumonia due to haemophilus influenzae, mycoplasma pneumoniae,

Bandaríkin - enska - NLM (National Library of Medicine)

physicians total care, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg in 5 ml - clarithromycin for oral suspension, usp is indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: adults pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae community-acquired pneumonia due to haemophilus i

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - clarithromycin -